The disclosure relates generally to a method and delivery system for transdermally administering a therapeutic polypeptide using an array of microstructures, and related features thereof.
Arrays of microneedles were proposed as a way of administering drugs through the skin in the 1970s, for example in expired U.S. Pat. No. 3,964,482. Microneedle or microstructure arrays can facilitate the passage of drugs through or into human skin and other biological membranes in circumstances where ordinary transdermal administration is inadequate. Microstructure arrays can also be used to sample fluids found in the vicinity of a biological membrane such as interstitial fluid, which is then tested for the presence of biomarkers.
Despite much initial work on fabricating microneedle arrays in silicon or metals, there are significant advantages to polymeric arrays. U.S. Pat. No. 6,451,240 discloses some methods of manufacturing polymeric microneedle arrays. Arrays made primarily of biodegradable polymers also have some advantages. U.S. Pat. No. 6,945,952 and U.S. Published Patent Applications Nos. 2002/0082543 and 2005/0197308 have some discussion of microneedle arrays made of biodegradable polymers. A detailed description of the fabrication of a microneedle array made of polyglycolic acid is found in Jung-Hwan Park et al., “Biodegradable polymer microneedles: Fabrication, mechanics, and transdermal drug delivery,” J. of Controlled Release, 104:51-66 (2005).
One increasing popular use for polymeric microneedles and microarrays currently undergoing development involves the use of biodegradable or soluble microneedles or microstructures for subcutaneous delivery of biomolecules. Therapeutic biomolecules showing promise include proteins, peptides and nucleic acids. Protein-based drugs are becoming increasing common and effective in the treatment of several conditions such as cancer and autoimmune diseases such as rheumatoid arthritis. Proteins are large and very complex molecules, having secondary and tertiary structures which usually must be preserved to maintain the therapeutic efficacy of the protein. This complex nature and accompanying stability issues make proteins difficult drug candidates for delivery. Currently, proteins are being predominantly administered by the parenteral route. However, this route of administration usually requires repeated administration due to the short half-life of such molecules. While oral, pulmonary and nasal routes of polypeptide delivery are also under development, these routes have limitations such as gastrointestinal degradation, low bioavailability and local irritation.
Use of transdermal delivery systems which can traverse the stratum corneum barrier and permeate into the deeper layers of the skin is a viable option for administration of therapeutic biologic molecules, including proteins. It has been reported that the skin has relatively low proteolytic activity as compared to mucosal routes. Thereby reducing the amount of protein degradation.
Accordingly, it would be of benefit to develop an effective means of delivering large biomolecules via microstructures and of making use of the advantages of microstructure array delivery.
The foregoing examples of the related art and limitations related therewith are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those of skill in the art upon a reading of the specification and a study of the drawings.
The following aspects and embodiments thereof described and illustrated below are meant to be exemplary and illustrative, not limiting in scope.
In a first aspect, an array of microstructures is provided comprising an approximately planar base and a plurality of microstructures comprising a drug, wherein each of the plurality of microstructures has mechanical strength sufficient to provide transdermal administration to a subject. The microstructure comprises a backing having a first surface and a second surface opposed thereto, and a microstructure array comprising the plurality of microstructures, wherein the plurality of microstructures extend outwardly from the first surface of the backing. Each of the plurality of microstructures comprises a biodegradable distal layer and at least one proximal layer positioned between the distal layer and the first surface of the backing. The distal layer comprises at least one drug and a stabilizing excipient.
In one embodiment, each of the plurality of microstructures does not comprise a structural polymer.
In one embodiment, the drug is a therapeutic macromolecule and the at least one therapeutic macromolecule is present in the distal layer in an amount which is about 30% to 90% of the distal layer.
In one embodiment, the at least one therapeutic macromolecule has a molecular weight of at least 20,000 Daltons (Da).
In one embodiment, the macromolecule is a polypeptide. In another embodiment, the macromolecule is a hormone. In still another embodiment, the macromolecule is an antibody or fragment thereof. In yet another embodiment, the macromolecule is a monoclonal antibody.
In one embodiment, the macromolecule is glycosylated.
In one embodiment, the macromolecule has a molecular weight of about 20,000 Da to 100,000 Da, 20,000 Da to 75,000 Da, 40,000 Da to 75,000 Da, 40,000 Da to 100,000 Da, 100,000 Da to 1,000,000 Da, 100,000 Da to 800,000 Da, 100,000 Da to 500,000 Da, 100,000 Da to 300,000 Da, 75,000 Da to 500,000 Da, 300,000 Da to 1,000,000 Da, 500,000 Da to 1,000,000 Da or 300,000 Da to 700,000 Da. In one embodiment, the molecular weight is that in the presence of or the absence of the glycosylation.
In one embodiment, the macromolecule is present in the distal layer at a concentration or amount of about 20% to 95%, 30% to 95%, 40% to 95%, 50% to 95%, 50% to 90%, 50% to 80%, 50% to 75%, 60% to 95%, 60% to 90%, 60% to 80%, 60% to 70%, 75% to 95% or 70% to 90% of the distal layer. In one embodiment, % is weight %.
In one embodiment the stabilizing excipient is a sugar. In another embodiment, the sugar is sucrose or trehalose. In still another embodiment, the sugar is present in each of the plurality of microstructures at a concentration of about 1% to 20%, 5% to 10%, 5% to 15%, 10% to 15% or 10% to 20%. In one embodiment, % is weight %.
In one embodiment, each of the plurality of microstructures comprises a surfactant. In another embodiment, the surfactant is sorbitol. In yet another embodiment, the surfactant is Polysorbate 80 and Polysorbate 20. In still another embodiment, the surfactant is present in each of the plurality of microstructures at a concentration of about 0.001% to 0.1%, 0.001% to 0.01%, 0.005% to 0.1%, 0.005% to 0.01%, 0.01% to 0.1%, 0.01% to 0.5%, 0.01% to 0.1%, 0.01% to 0.05%, or 0.02% to 0.07%, 0.1% to 1.0%, 0.01% to 1.0%, 0.001% to 1.0%, 0.1% to 5.0%, 1.0% to 5.0% of the distal layer. In one embodiment, % is weight %.
In one embodiment, each of the plurality of microstructures comprises an antioxidant. In another embodiment, the antioxidant is ethylenediaminetetraacetic acid (EDTA) or ascorbic acid. In still another embodiment, the antioxidant is present in each of the plurality of microstructures at a concentration of about 0.001% to 0.1%, 0.001% to 0.01%, 0.005% to 0.1%, 0.005% to 0.01%, 0.01% to 0.1%, 0.01% to 0.5%, 0.01% to 0.1%, 0.01% to 0.05%, or 0.02% to 0.07%, 0.1% to 1.0%, 0.01% to 1.0%, 0.001% to 1.0%, 0.1% to 5.0%, 1.0% to 5.0% of the distal layer. In one embodiment, % is weight %.
In a second aspect, method for making a microstructure array is provided, comprising: (a) mixing a polypeptide solution with a stabilizing excipient to form a polypeptide molding solution; (b) dispensing the polypeptide molding solution on a mold having an array of microstructure cavities; (c) filling the microstructure cavities in the mold; (f) removing excess solution or suspension polymer matrix on the mold surface; (g) drying the solution in a chamber having partial pressure of about 50 psi at a temperature of about 5° C. to 50° C.; (h) drying the solution at about 5° C. to 50° C. to form an array of microstructures; and (i) drying the microstructure under vacuum at about 5° C. to 50° C.
In one embodiment, the drying the solution to form an array of microstructures is at about 10° C. to 50° C., 10° C. to 40° C., 10° C. to 30° C., 15° C. to 50° C., 15° C. to 40° C., 15° C. to 30° C., 25° C. to 50° C., 25° C. to 35° C., or 32° C.
In one embodiment, the drying the microstructure under vacuum is at about 10° C. to 50° C., 10° C. to 40° C., 10° C. to 30° C., 15° C. to 50° C., 15° C. to 40° C., 15° C. to 30° C., 25° C. to 50° C., 25° C. to 35° C., or 32° C.
In one embodiment, the drying the basement or backing layer comprises drying in an oven at about 5° C. to 50° C., 10° C. to 50° C., 10° C. to 40° C., 10° C. to 30° C., 15° C. to 50° C., 15° C. to 40° C., 15° C. to 30° C., 25° C. to 50° C., 25° C. to 35° C., 30° C. to 40° C., 37° C., 35° C., or 32° C.
In one embodiment, the chamber uses convection, conduction or radiation for drying.
In one embodiment, the method further comprises (j) dispensing a basement or backing layer on the mold surface; and (k) drying the basement or backing layer.
In one embodiment, the method further comprises affixing the basement or backing layer to a substrate.
In one embodiment, the polypeptide molding solution is lyophilized then resuspended in water containing a surfactant prior to dispensing into the mold.
In a third aspect, a method for making a microstructure array is provided, comprising (a) mixing a polypeptide solution with a stabilizing excipient to form a polypeptide molding solution; (b) dispensing the polypeptide molding solution on a mold having an array of microstructure cavities; (c) filling the microstructure cavities in the mold; (f) removing excess solution or suspension polymer matrix on the mold surface; (g) drying the solution in a chamber having relative humidity of about 10% to 95% at a temperature of about 5° C. to 50° C.; (h) drying the solution at about 5° C. to 50° C. to form an array of microstructures; and (i) drying the microstructure under vacuum at about 5° C. to 50° C.
In one embodiment, the drying to solution in a chamber having humidity is done in a chamber having a relative humidity of about 25% to 90%, 50% to 85%, or 75% to 90%.
In one embodiment, the drying the solution to form an array of microstructures is at about 5° C. to 50° C., 10° C. to 50° C., 10° C. to 40° C., 10° C. to 30° C., 15° C. to 50° C., 15° C. to 40° C., 15° C. to 30° C., 25° C. to 50° C., 25° C. to 35° C., or 32° C.
In one embodiment, the drying the microstructure under vacuum is at about 5° C. to 50° C., 10° C. to 50° C., 10° C. to 40° C., 10° C. to 30° C., 15° C. to 50° C., 15° C. to 40° C., 15° C. to 30° C., 25° C. to 50° C., 25° C. to 35° C., or 32° C.
In one embodiment, drying the basement or backing layer comprises drying in an oven at about 5° C. to 50° C., 10° C. to 50° C., 10° C. to 40° C., 10° C. to 30° C., 15° C. to 50° C., 15° C. to 40° C., 15° C. to 30° C., 25° C. to 50° C., 25° C. to 35° C., or 32° C.
In one embodiment, the chamber uses convection, conduction or radiation for drying.
In one embodiment, the method further comprises: (j) dispensing a basement or backing layer on the mold surface; and (k) drying the basement or backing layer.
In one embodiment, the method further comprises affixing the basement or backing layer to a substrate.
In one embodiment, the polypeptide molding solution is lyophilized then resuspended in water containing a surfactant prior to dispensing into the mold.
In a fourth aspect, a method for administering a therapeutic macromolecule to a mammalian subject is provided, comprising inserting into the skin of the subject a microstructure array as described above.
Additional embodiments of the present microstructures, arrays, methods, and the like, will be apparent from the following description, drawings, examples, and claims. As can be appreciated from the foregoing and following description, each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present disclosure provided that the features included in such a combination are not mutually inconsistent. In addition, any feature or combination of features may be specifically excluded from any embodiment of the present invention. Additional aspects and advantages of the present invention are set forth in the following description and claims, particularly when considered in conjunction with the accompanying examples and drawings.
It will be appreciated that the thicknesses and shapes for the various microstructures have been exaggerated in the drawings to facilitate understanding of the device. The drawings are not necessarily “to scale.”
Various aspects now will be described more fully hereinafter. Such aspects may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey its scope to those skilled in the art.
The practice of the present disclosure will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g.; A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Morrison and Boyd, Organic Chemistry (Allyn and Bacon, Inc., current addition); J. March, Advanced Organic Chemistry (McGraw Hill, current addition); Remington: The Science and Practice of Pharmacy, A. Gennaro, Ed., 20th Ed.; Goodman & Gilman The Pharmacological Basis of Therapeutics, J. Griffith Hardman, L. L. Limbird, A. Gilman, 10th Ed.
Where a range of values is provided, it is intended that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1 μm to 8 μm is stated, it is intended that 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, and 7 μm are also explicitly disclosed, as well as the range of values greater than or equal to 1 μm and the range of values less than or equal to 8 μm.
As used in this specification, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “polymer” includes a single polymer as well as two or more of the same or different polymers; reference to an “excipient” includes a single excipient as well as two or more of the same or different excipients, and the like.
In describing and claiming the present invention, the following terminology will be used in accordance with the definitions described below.
“Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
“Substantially” or “essentially” means nearly totally or completely, for instance, 90-95% or greater of some given quantity.
“Hydrophobic polymer” as used herein refers to polymers that are insoluble or poorly soluble in aqueous solvents. “Hydrophilic polymer” as used herein refers to polymers that are soluble or substantially soluble in aqueous solvents.
The terms “microprotrusion”, “microprojection”, “microstructure” or “microneedle” are used interchangeably herein to refer to elements adapted to penetrate or pierce at least a portion of the stratum corneum or other biological membranes. For example, illustrative microstructures may include, in addition to those provided herein, microblades as described in U.S. Pat. No. 6,219,574, edged microneedles as described in U.S. Pat. No. 6,652,478, and microprotrusions as described in U.S. Patent Publication No. U.S. 2008/0269685 and U.S. 2009/0155330.
“Transdermal” refers to the delivery of an agent into and/or through the skin for local and/or systemic therapy. The same inventive principles apply to administration through other biological membranes such as those which line the interior of the mouth, gastro-intestinal tract, blood-brain barrier, or other body tissues or organs or biological membranes which are exposed or accessible during surgery or during procedures such as laparoscopy or endoscopy.
A material that is “water-soluble” may be defined as soluble or substantially soluble in aqueous solvents, such that the material dissolves into, within or below the skin or other membrane which is substantially aqueous in nature.
“Biodegradable” refers to natural or synthetic materials that degrade enzymatically, non-enzymatically or both to produce biocompatible and/or toxicologically safe by-products which may be eliminated by normal metabolic pathways.
The term “antibody” is used in the broadest sense and specifically covers monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyepitopic specificity, and antibody fragments (e.g., Fab, F(ab′)2, scFv and Fv), so long as they exhibit the desired biological activity. “Antibody” is meant to include polyclonal antibodies, monoclonal antibodies, humanized antibodies, human antibodies, primatized antibodies and other antibodies produced via genetic engineering.
The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by mammalian cell expression systems or transgenic technology, uncontaminated by other immunoglobulins. For example, the monoclonal antibodies to be used in accordance with the present invention may be expressed in goats, as described by Behboodi, et al. (2002) “Transgenic cloned goats and the production of therapeutic proteins.” In Principles of Cloning. Elsevier Science (USA); and Meade et al. (1999). “Expression of recombinant proteins in the milk of transgenic animals in Gene expression systems: using nature for the art of expression.” J. M. Fernandez and J. P. Hoeffler ed., Academic Press. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the methods described by Shepherd et al, Monoclonal Antibodies: A Practical Approach (Oxford University Press, 2000).
The term “monoclonal antibodies” also includes “chimeric” antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. For example, the ability to bind to alpha-4 integrin. The “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described for example in Clackson et al., 1991 Nature 352: 624-628 and Marks et al., 1991 J. Mol. Biol., 222: 581-597. “Humanized” forms of non-human (e.g., murine, rabbit, bovine, equine, porcine, and the like) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies), which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibody may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
A. Microstructure Array Composition
Provided herein are compositions and methods for transdermal administration of a therapeutic polypeptide using an array of microprojections. General features of microstructure arrays suitable for use in the instant arrays and methods are described in detail in U.S. Patent Publication No. 2008/0269685, U.S. Patent Publication No. 2009/0155330, U.S. Patent Publication No. 2011/0006458, and U.S. Patent Publication No. 2011/0276028, the entire contents of which are explicitly incorporated herein by reference.
Generally, the number of microstructures in the array is preferably at least about 50, at least about 100, at least about 500, at least about 1000, at least about 1400, at least about 1600, or at least about 2000. For example, the number of microstructures in the array may range from about 1000 to about 4000, or from about 2000 to about 4000, or from about 2000 to about 3500, or from about 2200 to about 3200. The area density of microstructures, given their small size, may not be particularly high, but for example the number of microstructures per cm2 may be at least about 50, at least about 250, at least about 500, at least about 750, at least about 1000, at least about 2000, or at least about 3000.
While the array itself may possess any of a number of shapes, the array is generally sized to possess a diameter of from about 5 millimeters (mm) to about 25 mm, or from about 7 mm to about 20 mm, or from about 8 mm to about 16 mm. Exemplary diameters include 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, and 25 mm.
The sizes of the microneedles and other protrusions for use with this invention will be a function of the manufacturing technology and of the precise application. In general, however, microstructures and other microprotrusions used in practice may be expected to have a height of at least about 20 μm to about 1000 μm, more preferably from about 50 μm to about 750 μm and most preferably from about 100 μm to about 500 μm. In specific, but not limiting embodiments, the microstructures have a height of at least about 100 μm, at least about 150 μm, at least about 200 μm, at least about 250 μm, or at least about 300 μm. In general it is also preferred that the microprojections have a height of no more than about 1 mm, no more than about 500 μm, no more than about 300 μm, or in some cases no more than about 200 μm or 150 μm. Often it will be desired that the microprotrusions will be long enough to penetrate at least partially through the stratum corneum layer of skin at some suitable point of application on the human body, for example the thigh, hip, arm, or torso. The microprojections may have an aspect ratio of at least 3:1 (height to diameter at base), at least about 2:1, or at least about 1:1.
The microprojections may have any suitable shape including, but not limited to polygonal or cylindrical. Particular embodiments include pyramidal including a four-sided pyramid, a funnel shape, a cylinder, a combination of funnel and cylinder shape having a funnel tip and a cylindrical base, and a cone with a polygonal bottom, for example hexagonal or rhombus-shaped. Other possible microprojection shapes are shown, for example, in U.S. Published Patent App. 2004/0087992 and in U.S. Application No. 61/745,513 filed Dec. 21, 2012. Microprojections may in some cases have a shape which becomes thicker towards the base, for example microprojections which have roughly the appearance of a funnel, or more generally where the diameter of the microprojection grows faster than linearly with distance to the microprojection distal end. It will be appreciate that polygonal microprojections may also have a shape which becomes thicker toward the base or where a radius or diameter grows faster than linearly with distance to the microprojection distal end. Where microprojections are thicker towards the base, a portion of the microprojection adjacent to the base, which may be called the “foundation,” may be designed not to penetrate the skin.
One illustrative shape for the microstructures is a cone with a polygonal bottom, for example, being hexagonal or rhombus-shaped. Additional microstructure shapes include those provided, for example, in U.S. Patent Publication No. 2004/0087992. In embodiments, at least a portion of the microstructure shape may be substantially cylindrical, cone-shaped, funnel-shaped, or pyramidal. In further embodiments, at least a portion of the microstructures has an asymmetrical cross-dimensional shape. Suitable asymmetric shapes include, but are not limited to, rectangular, square, oval, elliptical, circular, rhombus, triangular, polygonal, star-shaped, etc. In some embodiments, the distal layer has a cross-dimension in one direction that is smaller than the cross-dimension in the other direction. Exemplary cross-dimensional shapes with this configuration include, but are not limited to, rectangular, rhombus shaped, ellipse, and oval (see
Microstructure shape can be understood in terms of a tip, a shank and a funnel. The angle at the tip is the apex angle—included angle by the planes or cone—and can have values from about 5 degree to about 60 degrees. The straight or substantially straight shank may or may not be present in a particular microstructure design. At the base of the shank or tip, towards the distal end, the included angle has a discontinuity or a point of inflection. The included angle jumps to take on a value greater than the apex angle for a shank-less tip and to greater than 0 degrees for microstructures with a shank. Portions of the microstructure beyond this point of inflection may be referred to as a “funnel”.
The proximal funnel shape allows for relatively larger volumes to be dispensed in the microstructure mold for a given total length of the microstructure. The proximal funnel shape provides a larger volume (to fill) without requiring a proportional increase in microstructure height, which results in a longer drug containing portion in the microstructure. Thus, the proximal funnel shape allows for a larger solid volume for the distal portion of the microstructure with a single fill of the mold. Other shapes may require several fill and dry cycles to achieve the same amount of solid distal portion as one fill and dry cycle for the funnel shaped microstructures.
In one exemplary embodiment, at least a portion of the microstructures have a cylindrical funnel shape as shown in the array of
The funnel portion may also be used to limit the depth of penetration. Since the funnel has a several times higher volume per unit height than the tip or shank, it also requires several times higher energy to penetrate per unit depth than the tip or shank. Hence for a given energy, the microstructure would typically penetrate no more than the length of the tip and shank. The funnel thus effectively acts as the design element in the microstructure that limits the depth of penetration thereby ensuring tolerable sensation.
In embodiments, the microstructures have a sharp point or tip. A tip diameter of less than about 5 μm or 2 μm may be desirable. A tip diameter of less than about 1.5 μm is preferred, as is a tip diameter of less than about 1 μm.
The microprojections may be spaced about 0-500 μm apart. In specific, but not limiting embodiments, the microprojections are spaced about 0 μm, about 50 μm, about 100 μm, about 150 μm, about 200 μm, about 250 μm, about 300 μm, about 350 μm, about 400 μm, about 450 μm, or about 500 μm apart. The space between the microprojections may be measured from the base of the microprojections (base to base) or from the tip (tip to tip).
In further embodiments, at least a portion of the microprojections may be detachable from the microprojection array. Detachable microprojection arrays are described in U.S. Patent Publication 2009/0155330 and in U.S. Patent Application No. 61/745,513 filed Dec. 21, 2012, each of which is incorporated herein by reference. Detachable microprojection arrays may be accomplished by a number of approaches including, but not limited to, a layered approach in which the array is composed of multiple layers, and a layer comprising the areas where the microprojections attach to the base of the array is more readily degradable than other layers.
One potential advantage of detaching microprojections is elimination of sharp disposal requirements. Another potential advantage of detaching microprojections is elimination of needle stick injury. Another potential advantage of detaching microprojections is elimination of misuse, for example needle sharing, since the substrate without microprojections or with microprojections whose tips have been blunted due to biodegradation will not penetrate the skin. Another potential advantage of detaching microprojections is the avoidance of drug misuse because drug enriched tips are dissolved in the skin and no or minimal drug is left in the array.
Alternatively, an array made of a homogeneous material may be employed, in which the material is more readily degradable at lower pH's. Arrays made of such a material will tend to degrade more readily near the attachment points because these, being closer to the surface of the skin, are at a lower pH than the distal ends of the microprojections. (The pH of the skin's surface is generally lower than that of the skin further inwards, pH being for example approximately 4.5 on the surface and approximately 6.5 to 7.5 inward).
Materials whose solubility is dependent on pH can be, for example, insoluble in pure water but dissolve in acidic or basic pH environment. Using such materials or combination of materials, the arrays can be made to differentially biodegrade at the skin surface (pH approximately 4.5) or inside the skin. In the former, the whole array can biodegrade while in the latter, the microprojection portion of the array will biodegrade allowing the base substrate to be removed and discarded.
Materials whose degradability in an aqueous medium is dependent on pH may be made, for example, by utilizing the acrylate copolymers sold by Rohm Pharma under the brand name Eudragit, which are widely used in pharmaceutical formulation. A further example of a material with pH-dependent solubility is hydroxypropyl cellulose phthalate. Materials with pH-dependent solubility have been developed, for example, for use as enteric coatings in oral dosage forms. See, e.g., U.S. Pat. No. 5,900,252 and Remington's Pharmaceutical Sciences (18th ed. 1990).
It may also be desirable for the microprojection array of the invention to comprise one or more additional layers in addition to the layer which comprises the therapeutic agent. There are a number of reasons why arrays with multiple layers may be desirable. For example, it is often desirable that, compared to the whole volume of the microprojection array, the microprojections themselves have a higher concentration of active ingredient. This is so, for example, because the microprojections can be expected in many cases to dissolve more rapidly, being in a more hydrated environment than the base of the array. Furthermore, in some protocols for array application, the array may be left in for a short period of time during which essentially only the microprojections can dissolve to a substantial extent. The desirability of placing a higher concentration of active in the projections themselves is particularly acute when the active is costly. A way to achieve a higher concentration of active in the projections themselves is to have a first active-containing layer which includes the microprojections or a substantial proportion of the microprojections, and a second layer with a reduced or zero concentration of active which includes the base or a substantial proportion of the base.
B. Manufacturing Microprojection Arrays
Microprojection arrays as described herein may be fabricated by the techniques for the fabrication of two-layer arrays which are disclosed in U.S. Patent Publication No. 2008-0269685. The application of these techniques in the context of polypeptides is summarized here.
In general, an array is prepared by (a) providing a mold with cavities corresponding to the negative of the microprotrusions, (b) filling the mold with a casting solution comprising a pharmaceutically active agent and a solvent, (c) removing the solvent, and (d) demolding the resulting array from the mold. In one or more embodiments, the microprojections themselves comprise the active agent, as opposed to having the active agent present as a coating on a microprojection or microneedle made of a biocompatible material such as a metal.
The microstructure of the microstructure arrays referred to, for example, in U.S. Patent Publication No. 2008/0269685, U.S. Patent Publication No. 2009/0155330, U.S. Patent Publication No. 2011/0006458, and U.S. Patent Publication No. 2011/0276028 is usually comprised of polymer, excipients and the pharmaceutically active agent (API). A structure-forming polymer is added to provide mechanical strength and structure stability to the microprojections, enabling the microstructure to penetrate the skin. The polymer is also biocompatible, as well as inert to most APIs.
At least a portion of the microstructures as described in the patent publications referred to above is formed of a biodegradable, bioerodible, bioabsorbable and/or biocompatible polymer matrix. Biocompatible, biodegradable, bioabsorbable and/or bioerodible structure-forming polymers for use in the described microprojection arrays include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid)s (PLGAs), polyanhydrides, polyorthoesters, polyetheresters, polycaprolactones (PCL), polyesteramides, poly(butyric acid), poly(valeric acid), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), polyethylene glycol (PEG), block copolymers of PEG-PLA, PEG-PLA-PEG, PLA-PEG-PLA, PEG-PLGA, PEG-PLGA-PEG, PLGA-PEG-PLGA, PEG-PCL, PEG-PCL-PEG, PCL-PEG-PCL, copolymers of ethylene glycol-propylene glycol-ethylene glycol (PEG-PPG-PEG, trade name of Pluronic® or Poloxamer®), dextran, hetastarch, tetrastarch, pentastarch, hydroxyethyl starches, cellulose, hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose (Na CMC), thermosensitive HPMC (hydroxypropyl methyl cellulose), polyphosphazene, hydroxyethyl cellulose (HEC), other polysaccharides, polyalcohols, gelatin, alginate, chitosan, hyaluronic acid and its derivatives, collagen and its derivatives, polyurethanes, and copolymers and blends of these polymers. A preferred hydroxyethyl starch for this use has a degree of substitution of in the range of 0-0.9.
The biodegradability or dissolvability of the microprojection arrays as described in the above-referenced patent publications may be facilitated by the inclusion of one or more sugar. Exemplary sugars include dextrose, fructose, galactose, maltose, maltulose, iso-maltulose, mannose, lactose, lactulose, sucrose, and trehalose. Sugar alcohols, for example lactitol, maltitol, sorbitol, and mannitol, may also be employed. Cyclodextrins can also be used advantageously in microneedle arrays, for example α, β, and γ cyclodextrins, for example hydroxypropyl-β-cyclodextrin and methyl-β-cyclodextrin. Sugars and sugar alcohols may also be helpful in stabilization of peptides and proteins and in modifying the mechanical properties of the microprojections by exhibiting a plasticizing-like effect.
The biodegradability of a microstructure array as described in the above-referenced patent publications may also be facilitated by inclusion of water-swellable polymers such as crosslinked PVP, sodium starch glycolate, crosslinked polyacrylic acid, crosscarmellose sodium, celluloses, natural and synthetic gums, polysaccharides, or alginates. In a multilayer array, the sugars and other polymers which facilitate biodegradability may be located only in a layer or layers which encompass the microprojections. These polymers may also be used as structure-forming polymers.
Further, the structure-forming polymers used in a microstructure array as described in the above-referenced patent publications may possess a variety and range of molecular weights. The polymers may, for example, have molecular weights of at least about 1K Da, at least about 5K Da, at least about 10K Da, at least about 20K Da, at least about 30K Da, at least about 50K Da, or at least about 100K Da. Where the microstructure is meant to be biodegradable, it may be desired to have biodegradable portion(s) comprise one or more polymers having a lower molecular weight. The strength-molecular weight relation in polymers is an inverse relation so structure-forming polymers with lower molecular weights have a lower strength and will tend to be more biodegradable. Further polymers with a lower molecular weight will be more likely to break due to the lower strength. In embodiments described in the above-reference patent publications, at least the distal layer comprises at least one structure-forming polymer having a lower molecular weight. In an embodiment, at least the distal layer comprises at least one structure-forming polymer having a molecular weight less than about 100K Da. In another embodiment, at least the distal layer comprises at least one structure-forming polymer having a molecular weight less than about 20K Da. In other embodiments, at least the distal layer comprises at least one structure-forming polymer having a molecular weight less than about 1K Da, less than about 5K Da, less than about 10K Da, less than about 15K Da or less than about 20K Da. In one embodiment, at least the distal layer comprises at least one structure-forming polymer having a molecular weight of between about 1K-100K Da or between about 1K-20K Da. In other embodiments, the distal layer comprises at least one structure-forming polymer having a molecular weight of between about 1K-100K Da, between about 1000-5000 Da, between about 1000-10,000 Da, between about 1000-15,000 Da, between about 5000-10,000 Da, between about 5000-15,000 Da, between about 5000-20,000 Da, between about 10,000-15,000 Da, between about 10,000-20,000 Da, and between about 15,000-20,000 Da.
Nevertheless, the polymer may sometimes not be compatible with a particular API, resulting in difficult challenges for loading such APIs. For this reason it is desirable to develop a structure-forming polymer-free microstructure which may be used for formulation of APIs which are incompatible with polymers in use for microstructure arrays as described above.
A. Structure-Forming Polymer-Free Microstructure Compositions
As described in more detail below, it was unexpectedly found that formulation of a polymer-free microstructure is capable of forming a solid microstructure with mechanical strength sufficient for penetrating skin if the API has a high enough molecular weight. Such microstructures are formulated using a solution of a high molecular weight macromolecule in solution with a stabilizing excipient such as sorbitol, sucrose, or trehalose. In some embodiments, a macromolecule solution is lyophilized then reconstituted with water containing a surfactant (e.g., Polysorbate 20) to a formulation with a macromolecule concentration greater than about 200 mg/ml.
Importantly, without adding any of the structure-forming polymers described above with reference to U.S. Patent Publication No. 2008/0269685, U.S. Patent Publication No. 2009/0155330, U.S. Patent Publication No. 2011/0006458, and U.S. Patent Publication No. 2011/0276028, to the polypeptide solution, before or after lyophilization and reconstitution, the casting solution dispensed into the microarray mold will produce a microstructure capable of penetrating the skin and administering the macromolecule. More specifically, the distal layer of the microstructure does not comprise a structure-forming polymer.
The structure-forming polymer-free microstructures as described in more detail below are able to release the incorporated macropolymer into a subcutaneous layer over an extended period of time.
In a preferred embodiment, the macromolecule is a polypeptide or peptide. Glycosylation of the polypeptide to peptide may increase the molecular weight and may impart structural and/or mechanical strength of the microstructure into which the macromolecule is formulated.
It is thought that the high molecular weight structure of the macromolecule provides the necessary mechanical strength to the microstructure. Such polypeptides may have a molecular weight of at least 100,000 Daltons (Da), or between about 100,000 Da and about 1,000,000 Da.
Alternatively, smaller polypeptides (peptides), having a molecular weight of about 10,000 Da to about 100,000 Da, may be formulated into the microstructures. In some embodiments, these peptides are glycosylated to produce an API with a larger molecular weight and molecular radius, thereby imparting the necessary mechanical strength to the microstructure.
Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
Addition of glycosylation sites to the polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).
Examples of peptides and proteins which may be used with the microstructure arrays include, but are not limited to, parathyroid hormone (PTH), oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), prolactin, luteinizing hormone, follicle stimulating hormone, luliberin or luteinizing hormone releasing hormone (LHRH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, kyotorphin, taftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor, serum thymic factor, tumor necrosis factor, colony stimulating factors, motilin, bombesin, dinorphin, neurotensin, cerulein, bradykinin, urokinase, kallikrein, substance P analogues and antagonists, angiotensin II, nerve growth factor, blood coagulation factors VII and IX, lysozyme chloride, renin, bradykinin, tyrocidin, gramicidines, growth hormones, melanocyte stimulating hormone, thyroid hormone releasing hormone, thyroid stimulating hormone, pancreozymin, cholecystokinin, human placental lactogen, human chorionic gonadotropin, protein synthesis stimulating peptide, gastric inhibitory peptide, vasoactive intestinal peptide, platelet derived growth factor, growth hormone releasing factor, bone morphogenic protein, and synthetic analogues and modifications and pharmacologically active fragments thereof. Peptidyl drugs also include synthetic analogs of LHRH, e.g., buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide (leuprorelin), lutrelin, nafarelin, tryptorelin, and pharmacologically active salts thereof. Administration of oligonucleotides is also contemplated, and includes DNA and RNA, other naturally occurring oligonucleotides, unnatural oligonucleotides, and any combinations and/or fragments thereof. Currently marketed therapeutic antibodies include but are not limited to Orthoclone OKT3 (muromonab CD3), ReoPro (abciximab), Rituxan (rituximab), Zenapax (daclizumab), Remicade (infliximab), Simulect (basiliximab), Synagis (palivizumab), Herceptin (trastuzumab), Mylotarg (gemtuzumab ozogamicin), CroFab, DigiFab, Campath (alemtuzumab), and Zevalin (ibritumomab tiuxetan).
The polypeptide solution generated to make a polypeptide casting or molding solution may have a polypeptide concentration of at least 10 mg/ml to about 400 mg/ml.
The polypeptide solution containing the therapeutic polypeptide may comprise a stabilizing excipient, including but not limited to, polyols, sugars, amino acids, amines, and salting out salts. Sucrose and trehalose are the most frequently used sugars and large polyols are in general better stabilizers than smaller polyols. Additional sugars which may be used include, but are not limited to, fructose and dextrose. Hydrophilic polymers, such as polyethylene glycols (PEGs), polysaccharides, and inert proteins, are used to non-specifically to stabilize proteins and enhance protein assembly. Examples include dextran, hydroxyl ethyl starch (HETA), PEG-4000, and gelatin. Smaller PEGs have been found to be less effective than larger ones. Additionally, non-polar moieties on certain polymers such as PEGs and Pluronics can decrease water surface tension rendering them as surfactants that suppress surface adsorption induced aggregation. Non-ionic surfactants are widely used to stabilize proteins, suppress aggregation, and assist in protein refolding. Polysorbate 80 and Polysorbate 20, also known as Tween 80 and Tween 20, respectively, have been widely incorporated in marketed protein pharmaceuticals at 0.0003-0.3% range. Other examples include Brij 35, Triton X-10, Pluronic F127, and sodium doceyl sulfate (SDS). Amino acids. These excipients stabilize proteins by a variety of mechanisms. Examples include histidine, arginine, and glycine. Other amino acids used as formulation excipients include methionine, proline, lysine, glutamic acid, and arginine mixtures.
B. Methods for Making Structure-Forming Polymer-Free Microstructures
The microarray microstructures are constructed using a solution of a polypeptide. The solution is preferably an aqueous solution which may be buffered, such as with a phosphate buffered saline at a pH of about 5.0 to 8.0, or about 6.5 to 7.5, which helps to preserve the native structure of the polypeptide. Alternatively, the solution is buffered with a histidine buffer, with a pH of about 5.0 to 7.0 or 5.5 to 6.5 or about 6.0. In some embodiments, a stabilizing excipient such as a sugar is added to the solution. When concentrations greater than about 100 mg/ml or 200 mg/ml are desired for therapeutically effective administrations, the solution may be lyophilized and reconstituted in an appropriate volume of a buffered aqueous solution. Reconstitution of the lyophilized polypeptide composition may be done in water for injection which contains a surfactant such as Polysorbate 20 or Polysorbate 80. The polypeptide solutions for casting may further comprise an antioxidant such as ethylenediaminetetraacetic (EDTA), glutathione, methionine, cysteine, D-alpha tocopherol aceta, vitamin E or ascorbic acid. Suitable components are nontoxic to recipients at the dosages and concentrations employed. Further examples of components that may be employed in pharmaceutical formulations are presented in Remington's Pharmaceutical Sciences, 16th Ed. (1980) and 20th Ed. (2000), Mack Publishing Company, Easton, Pa.
The polypeptide casting composition is then dispensed over a microstructure mold and dried in a chamber having a relative humidity of at least about 10%. In some preferred embodiments, the relative humidity is about 80% to 90%. This chamber is set at a temperature ranging from about 20° C. to 50° C. but is preferably about 25° C. to 30° C. The mold is then dried in an oven set at about 5° C. to 50° C., or more generally about 30° C. to 35° C. The oven may dry the mold via convention, conduction or radiation heat.
When the microstructure arrays comprising the structure-forming polymer-free microstructures formulated with a macromolecule are administered to the skin of a mammal, the microstructures have the structural and mechanical strength sufficient to allow each microstructure to penetrate the skin at an efficiency which is at least as efficient as a microstructure formulated with a structure-forming polymer as described in previous patent publications detailed above.
The final microstructure array when fabricated as described herein contains about 1 mg to 25 mg, 2 mg to 20 mg, 5 mg to 15 mg, 1 mg to 10 mg, 2 mg to 80 mg, 4 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 10 mg to 15 mg, 13 mg to 17 mg, 15 mg to 20 mg, or 5 mg to 15 mg of the macromolecule for administration to a subject.
Importantly, the macromolecules formulated within the structure-forming polymer-free microstructures remain stable and therapeutically effective. Stability of the released macromolecule may be measured using a variety of methods, including but not limited to, measurement of aggregation and oxidation. To measure aggregation, macromolecules released by or extracted from structure-forming polymer-free microstructures are analyzed for the formation of high molecular mass species using size exclusion high performance liquid chromatograph (SEC-HPLC). Oxidation of methionine residues are monitored using, for example, a Lys-C proteolysis mapping assay and reverse phase HPLC.
The methods, kits, microstructure arrays and related devices described herein may be used for treating any condition. It will be appreciated that the microstructure arrays may be used with any appropriate applicator including the applicator described in U.S. Publication No. 2011/0276027, which is incorporated by reference herein in its entirety.
The following examples are illustrative in nature and are in no way intended to be limiting. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. and pressure is at or near atmospheric.
A solution containing a monoclonal antibody is mixed with a stabilizing excipient such as sucrose or trehalose to form an antibody concentration of about 50 mg/ml to 100 mg/ml. To create a solution with a monoclonal antibody concentration greater than about 100 mg/ml or 200 mg/ml, the solution is lyophilized, then reconstituted with water for injection (WFI) containing a surfactant such as sorbitol for drug-in-tip (DIT) formulations for casting microstructures.
About 75 μL of liquid DIT formulation is dispensed on a silicone mold, covered with a 22 mm×30 mm glass cover slip to spread the formulation on the mold, and then pressurized for 1 minute at about 40 to 60 psi. The formulation is then wiped and the mold dried in a chamber with about 80% to 90% relative humidity (RH), at room temperature for about 10 to 15 minutes. The mold is then incubated for about 30 minutes in an oven at about 30° C. to 35° C. A polylactide-co-glycolide (PLGA) layer is then casted onto array to connect the microstructures.
The construct is dried in a compressed dry air box for about 30 minutes, and then in a convection oven at about 40° C. to 50° C. for about 30 minutes.
UV adhesive is then dispensed on the top of the PLGA layer, covered with 5 ml polycarbonate (PC) film to spread the adhesive, and then cured using a UV Fusion system. The UV curing dose is about 1.6 J/cm2. After curing the microstructure array comprising the DIT layer, PLGA layer, and UV adhesive backing layer on PC, the structure is die cut with an 11 mm or 16 mm punch. The microstructure array is dried under full vacuum at room temperature overnight followed by full vacuum at about 30° C. to 40° C. for 6 hours. The microstructures were pouched individually with desiccant in polyfoil pouches.
Effects of the microstructure formulation on stability of the monoclonal antibody are assessed by measuring oxidation of methionine residues in the monoclonal antibody. This is done by Lys-C proteolytic mapping using reverse phase HPLC.
Monoclonal antibody is extracted from the microstructure by submerging the microstructure in 20 mM acetate buffer with 0.05% Tween 20 for approximately 1 hour on a low speed shaker. The extraction is analyzed by Lys-C proteolysis and size exclusion high performance liquid chromatography (SEC-HPLC) for monitoring aggregation.
Changes in High Molecular Mass species (HMMs) and methionine oxidation are monitored over 4 weeks at 5° C., 25° C. and 40° C. If the monoclonal antibody remains stable when formulated as described above, there will be no significant increase in HMMs of the monoclonal antibody, compared to the initial material (API bulk).
Experiments are performed to assess the mechanical strength and penetration efficiency of the microstructure arrays formulated as described in Example 1. In vitro performance is characterized by the microstructure array's ability to penetrate excised pig skin as compared to a microstructure array fabricated using structure-forming polymers.
Full-thickness pig skin is excised from the abdomen and then clipped and shaved to remove hair bristles. Microstructure arrays are applied to shaved skin sites using a reusable application and held by hand in situ for about 5 to 15 minutes. Application sites are stained and photographed to visualize the microstructure penetrations. Penetrations are quantified using a custom developed image analysis program. Skin penetration efficiency (SPE) is then calculated based on the theoretical number of microstructures expected for the constructed microstructure array as follows:
% SPE=100×(no. penetrations/no. microstructures)
If the microstructure arrays fabricated with and without structure-forming polymers show equivalent SPE, it can be concluded that microstructure arrays having microstructures void of structure-forming polymers are equivalently strong and effective as those having a microstructure containing a structure-forming polymer.
In vitro skin penetration efficiency experiments can also be done to compare the strength of microstructures in the presence of difference stabilizing excipients. Microstructure arrays are fabricated as described above in which microstructures are formulated with either sucrose or trehalose as a protein stabilizer. The arrays are then applied to shaved skin sites on pig skin using a reusable application and held by hand in situ for about 5 to 15 minutes. Equally excellent SPE using both arrays indicate that strong mechanical strength is achieved when using different sugars as the stabilizing excipient.
The effects of humidity on skin penetration efficiency is also tested is a similar manner as above. The microstructure arrays are exposed to 65% relative humidity for 10 minutes. The SPE of microstructure arrays which are or are not exposed to 65% relative humidity are then compared. If both arrays have a high SPE (e.g., greater than 80%), this indicates that the microstructure array, even in the absence of structure-forming polymer, is mechanically strong, even after exposure to a humid environment. Like structure-forming polymer-containing microstructure arrays, the polymer-free microstructure arrays have both good mechanical performance and high humidity tolerance.
While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such modifications, permutations, additions and sub-combinations as are within their true spirit and scope.
A solution containing a polypeptide is mixed with either sucrose or trehalose as a stabilizing excipient. The solution is then lyophilized and reconstituted with water for injection (WFI) containing Polysorbate 20 (PS20) to form a polypeptide casting solution with a polypeptide concentration greater than 200 mg/ml for casting the microstructures.
About 75 μL of liquid DIT formulation is dispensed on a silicone mold, covered with a 22 mm×30 mm glass cover slip to spread the formulation on the mold, and then pressurized at 50 psi for 1 minute. The formulation is then wiped and the mold dried in a chamber with 85% relative humidity (RH), at room temperature for 10 minutes. The mold was then incubated for about 30 minutes in an oven at 32° C. A polylactide-co-glycolide (PLGA) layer was casted on the array to connect the microstructures.
The construct is dried in a compressed dry air box for 30 minutes, and then dried by convection, conduction or radiation at 45° C. for 30 minutes.
UV adhesive is then dispensed on the top of the PLGA layer, covered with 5 ml polycarbonate (PC) film to spread the adhesive, and then cured using a UV Fusion system. The UV curing dose is about 1.6 J/cm2. After curing the microstructure array comprising the DIT layer, PLGA layer, and UV adhesive backing layer on PC, the structure was die cut with an 11 mm or 16 mm punch. The microstructure array is dried under full vacuum at room temperature overnight followed by full vacuum at 35° C. for 6 hours. The microstructures are pouched individually with desiccant in polyfoil pouches.
All patents, patent applications, and publications mentioned herein are hereby incorporated by reference in their entireties. However, where a patent, patent application, or publication containing express definitions is incorporated by reference, those express definitions should be understood to apply to the incorporated patent, patent application, or publication in which they are found, and not necessarily to the text of this application, in particular the claims of this application, in which instance, the definitions provided herein are meant to supersede.
This application claims the benefit of U.S. Provisional Application No. 61/792,715, filed Mar. 15, 2013, which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
1554510 | Kirby | Sep 1925 | A |
1770632 | Smith | Jul 1930 | A |
2046240 | Bayley | Jun 1936 | A |
2434407 | George | Jan 1948 | A |
3675766 | Rosenthal | Jul 1972 | A |
3704194 | Harrier | Nov 1972 | A |
3814097 | Ganderton et al. | Jun 1974 | A |
3873255 | Kalwaites | Mar 1975 | A |
3918449 | Pistor | Nov 1975 | A |
3964482 | Gerstel et al. | Jun 1976 | A |
4055029 | Kalbow | Oct 1977 | A |
4117841 | Perrotta et al. | Oct 1978 | A |
4151240 | Lucas et al. | Apr 1979 | A |
4180232 | Hardigg | Dec 1979 | A |
4342314 | Radel et al. | Aug 1982 | A |
4381963 | Goldstein et al. | May 1983 | A |
4395215 | Bishop | Jul 1983 | A |
4402696 | Gulko | Sep 1983 | A |
4460368 | Allison et al. | Jul 1984 | A |
4460370 | Allison et al. | Jul 1984 | A |
4463045 | Ahr et al. | Jul 1984 | A |
4509908 | Mullane, Jr. | Apr 1985 | A |
4515168 | Chester et al. | May 1985 | A |
4556441 | Faasse, Jr. | Dec 1985 | A |
4585991 | Reid et al. | Apr 1986 | A |
4597961 | Etscorn | Jul 1986 | A |
4609518 | Curro et al. | Sep 1986 | A |
4630603 | Greenway | Dec 1986 | A |
4660721 | Mykleby | Apr 1987 | A |
4695422 | Curro et al. | Sep 1987 | A |
4743234 | Leopoldi et al. | May 1988 | A |
4743249 | Loveland | May 1988 | A |
4784737 | Ray et al. | Nov 1988 | A |
4812305 | Vocal | Mar 1989 | A |
4837049 | Byers et al. | Jun 1989 | A |
4846821 | Lyons et al. | Jul 1989 | A |
4904475 | Gale et al. | Feb 1990 | A |
4996159 | Glaser | Feb 1991 | A |
5051259 | Olsen et al. | Sep 1991 | A |
5061258 | Martz | Oct 1991 | A |
5134079 | Cusak et al. | Jul 1992 | A |
5139029 | Fishman et al. | Aug 1992 | A |
5156591 | Gross et al. | Oct 1992 | A |
5158073 | Bukowski | Oct 1992 | A |
5160315 | Heinecke et al. | Nov 1992 | A |
5162043 | Lew et al. | Nov 1992 | A |
5163918 | Righi et al. | Nov 1992 | A |
5190558 | Matsushita et al. | Mar 1993 | A |
5198192 | Saito et al. | Mar 1993 | A |
5215088 | Normann et al. | Jun 1993 | A |
5244677 | Kreckel et al. | Sep 1993 | A |
5244711 | Drelich et al. | Sep 1993 | A |
5250023 | Lee et al. | Oct 1993 | A |
5250067 | Gelfer et al. | Oct 1993 | A |
5252279 | Gore et al. | Oct 1993 | A |
5256360 | Li | Oct 1993 | A |
5279544 | Gross et al. | Jan 1994 | A |
5308625 | Wong et al. | May 1994 | A |
5318557 | Gross | Jun 1994 | A |
5320600 | Lambert | Jun 1994 | A |
5330452 | Zook | Jul 1994 | A |
5362307 | Guy et al. | Nov 1994 | A |
5383512 | Jarvis | Jan 1995 | A |
5457041 | Ginaven et al. | Oct 1995 | A |
5462743 | Turner et al. | Oct 1995 | A |
5476443 | Cartmell et al. | Dec 1995 | A |
5487726 | Rabineau et al. | Jan 1996 | A |
5496304 | Chasan | Mar 1996 | A |
5498235 | Flower | Mar 1996 | A |
5503843 | Santus et al. | Apr 1996 | A |
5512219 | Rowland et al. | Apr 1996 | A |
5520629 | Heinecke et al. | May 1996 | A |
5527287 | Miskinyar | Jun 1996 | A |
5527288 | Gross et al. | Jun 1996 | A |
5531675 | Yoo | Jul 1996 | A |
5531855 | Heinecke et al. | Jul 1996 | A |
5536263 | Rolf et al. | Jul 1996 | A |
5551953 | Lattin et al. | Sep 1996 | A |
5567376 | Turi et al. | Oct 1996 | A |
5569469 | Lovrechich | Oct 1996 | A |
5591123 | Sibalis et al. | Jan 1997 | A |
5591139 | Lin et al. | Jan 1997 | A |
5611806 | Jang | Mar 1997 | A |
5645977 | Wu et al. | Jul 1997 | A |
5658515 | Lee et al. | Aug 1997 | A |
5662127 | De Vaughn | Sep 1997 | A |
5676850 | Reed et al. | Oct 1997 | A |
5681580 | Jang et al. | Oct 1997 | A |
5697901 | Ericksson | Dec 1997 | A |
5704520 | Gross | Jan 1998 | A |
5711761 | Untereker et al. | Jan 1998 | A |
5728089 | Lal et al. | Mar 1998 | A |
5730714 | Guy et al. | Mar 1998 | A |
5730721 | Hyatt et al. | Mar 1998 | A |
5735273 | Kurnik et al. | Apr 1998 | A |
5738642 | Heinecke et al. | Apr 1998 | A |
5756117 | D'Angelo et al. | May 1998 | A |
5771890 | Tamada | Jun 1998 | A |
5788983 | Chien et al. | Aug 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5807375 | Gross et al. | Sep 1998 | A |
5814020 | Gross | Sep 1998 | A |
5820622 | Gross et al. | Oct 1998 | A |
5827183 | Kurnik et al. | Oct 1998 | A |
5843114 | Jang | Dec 1998 | A |
5848985 | Muroki | Dec 1998 | A |
5848990 | Cirelli et al. | Dec 1998 | A |
5848991 | Gross et al. | Dec 1998 | A |
5851549 | Svec | Dec 1998 | A |
5855801 | Lin et al. | Jan 1999 | A |
5868244 | Ivanov et al. | Feb 1999 | A |
5873849 | Bernard | Feb 1999 | A |
5879326 | Godshall et al. | Mar 1999 | A |
5900252 | Calanchi et al. | May 1999 | A |
5932240 | D'Angelo et al. | Aug 1999 | A |
5938684 | Lynch et al. | Aug 1999 | A |
5948488 | Marecki et al. | Sep 1999 | A |
5962011 | Devillez et al. | Oct 1999 | A |
5964729 | Choi et al. | Oct 1999 | A |
5983136 | Kamen | Nov 1999 | A |
5987989 | Yamamoto et al. | Nov 1999 | A |
5997549 | Sauceda et al. | Dec 1999 | A |
5997986 | Turi et al. | Dec 1999 | A |
6014584 | Hofmann et al. | Jan 2000 | A |
6023629 | Tamada | Feb 2000 | A |
6024553 | Shimalla | Feb 2000 | A |
6036659 | Ray et al. | Mar 2000 | A |
6038465 | Melton, Jr. | Mar 2000 | A |
6038485 | Axelgaard | Mar 2000 | A |
6047208 | Flower | Apr 2000 | A |
6050988 | Zuck | Apr 2000 | A |
6055453 | Hofmann et al. | Apr 2000 | A |
6080172 | Fujiwara et al. | Jun 2000 | A |
6083196 | Trautman et al. | Jul 2000 | A |
6091975 | Daddona et al. | Jul 2000 | A |
6106751 | Talbot et al. | Aug 2000 | A |
6120792 | Juni | Sep 2000 | A |
6129696 | Sibalis | Oct 2000 | A |
6132449 | Lum et al. | Oct 2000 | A |
6132755 | Eicher et al. | Oct 2000 | A |
6135990 | Heller et al. | Oct 2000 | A |
6136008 | Becker et al. | Oct 2000 | A |
6156336 | Bracht | Dec 2000 | A |
6169224 | Heinecke et al. | Jan 2001 | B1 |
6181964 | Hofmann et al. | Jan 2001 | B1 |
6183434 | Eppstein | Feb 2001 | B1 |
6183770 | Muchin et al. | Feb 2001 | B1 |
6187210 | Lebouitz et al. | Feb 2001 | B1 |
6216034 | Hofmann et al. | Apr 2001 | B1 |
6219574 | Cormier et al. | Apr 2001 | B1 |
6230051 | Cormier et al. | May 2001 | B1 |
6241701 | Hofmann | Jun 2001 | B1 |
6248120 | Wyszogrodzki | Jun 2001 | B1 |
6256533 | Yuzhakov et al. | Jul 2001 | B1 |
6293925 | Safabash et al. | Sep 2001 | B1 |
6312612 | Sherman et al. | Nov 2001 | B1 |
6322808 | Trautman et al. | Nov 2001 | B1 |
6334856 | Allen et al. | Jan 2002 | B1 |
6355054 | Neuberger | Mar 2002 | B1 |
6375627 | Mauze et al. | Apr 2002 | B1 |
6375870 | Visovsky et al. | Apr 2002 | B1 |
6375978 | Kleiner et al. | Apr 2002 | B1 |
6379324 | Garstein et al. | Apr 2002 | B1 |
6440096 | Lastovich et al. | Aug 2002 | B1 |
6451240 | Sherman et al. | Sep 2002 | B1 |
6471903 | Sherman et al. | Oct 2002 | B2 |
6476288 | Van Rijswijck et al. | Nov 2002 | B1 |
6485470 | Hostettler et al. | Nov 2002 | B2 |
6494830 | Wessel | Dec 2002 | B1 |
6503231 | Prausnitz et al. | Jan 2003 | B1 |
6508947 | Gulvin et al. | Jan 2003 | B2 |
6511463 | Wood et al. | Jan 2003 | B1 |
6512626 | Schmidt | Jan 2003 | B1 |
6516223 | Hofmann | Feb 2003 | B2 |
6532386 | Sun et al. | Mar 2003 | B2 |
6533884 | Mallik | Mar 2003 | B1 |
6537242 | Palmer | Mar 2003 | B1 |
6537264 | Cormier et al. | Mar 2003 | B1 |
6558361 | Yeshurun | May 2003 | B1 |
6562014 | Lin et al. | May 2003 | B2 |
6565532 | Yuzhakov et al. | May 2003 | B1 |
6585742 | Stough | Jul 2003 | B2 |
6589202 | Powell | Jul 2003 | B1 |
6591124 | Sherman et al. | Jul 2003 | B2 |
6591133 | Joshi | Jul 2003 | B1 |
6603987 | Whitson | Aug 2003 | B2 |
6610463 | Ohkura et al. | Aug 2003 | B1 |
6611706 | Avrahami et al. | Aug 2003 | B2 |
6611707 | Prausnitz et al. | Aug 2003 | B1 |
6623457 | Rosenberg | Sep 2003 | B1 |
6629949 | Douglas | Oct 2003 | B1 |
6652478 | Garstein et al. | Nov 2003 | B1 |
6656147 | Gertsek et al. | Dec 2003 | B1 |
6663820 | Arias et al. | Dec 2003 | B2 |
6685682 | Heinecke et al. | Feb 2004 | B1 |
6689103 | Palasis | Feb 2004 | B1 |
6691752 | DiSabatino | Feb 2004 | B2 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6767341 | Cho | Jul 2004 | B2 |
6770480 | Canham | Aug 2004 | B1 |
6778853 | Heller et al. | Aug 2004 | B1 |
6780171 | Gabel et al. | Aug 2004 | B2 |
6808506 | Lastovich et al. | Oct 2004 | B2 |
6821281 | Sherman et al. | Nov 2004 | B2 |
6835184 | Sage et al. | Dec 2004 | B1 |
6855131 | Trautman et al. | Feb 2005 | B2 |
6881203 | Delmore et al. | Apr 2005 | B2 |
6931277 | Yuzhakov et al. | Aug 2005 | B1 |
6945952 | Kwon | Sep 2005 | B2 |
6960193 | Rosenberg | Nov 2005 | B2 |
6980855 | Cho et al. | Dec 2005 | B2 |
6991809 | Anderson | Jan 2006 | B2 |
7011844 | Gale et al. | Mar 2006 | B2 |
7048723 | Frazier et al. | May 2006 | B1 |
7062317 | Avrahami et al. | Jun 2006 | B2 |
7087035 | Trautman et al. | Aug 2006 | B2 |
7097631 | Trautman et al. | Aug 2006 | B2 |
7108681 | Gartstein et al. | Sep 2006 | B2 |
7115108 | Wilkinson et al. | Oct 2006 | B2 |
7128730 | Marano-Ford et al. | Oct 2006 | B2 |
7131960 | Trautman et al. | Nov 2006 | B2 |
7131987 | Sherman et al. | Nov 2006 | B2 |
7166086 | Haider et al. | Jan 2007 | B2 |
7184826 | Cormier et al. | Feb 2007 | B2 |
7186235 | Martin et al. | Mar 2007 | B2 |
7226439 | Prausnitz et al. | Jun 2007 | B2 |
7332339 | Canham | Feb 2008 | B2 |
7412284 | Hofmann | Aug 2008 | B2 |
7416541 | Yuzhakov et al. | Aug 2008 | B2 |
7419481 | Trautman et al. | Sep 2008 | B2 |
7572405 | Sherman et al. | Aug 2009 | B2 |
7578954 | Gartstein et al. | Aug 2009 | B2 |
7578985 | Gartstein et al. | Aug 2009 | B2 |
7611481 | Cleary et al. | Nov 2009 | B2 |
7658728 | Yuzhakov | Feb 2010 | B2 |
7678777 | Yasuda et al. | Mar 2010 | B2 |
7763203 | Arias et al. | Jul 2010 | B2 |
7785301 | Yuzhakov | Aug 2010 | B2 |
7789733 | Sugimura | Sep 2010 | B2 |
7798987 | Trautman et al. | Sep 2010 | B2 |
7828827 | Gartstein et al. | Nov 2010 | B2 |
7846488 | Johnson | Dec 2010 | B2 |
7914480 | Cleary et al. | Mar 2011 | B2 |
8057842 | Choi et al. | Nov 2011 | B2 |
8062573 | Kwon | Nov 2011 | B2 |
8216190 | Gartstein et al. | Jul 2012 | B2 |
8267889 | Cantor et al. | Sep 2012 | B2 |
8366677 | Kaspar et al. | Feb 2013 | B2 |
8696638 | Terahara et al. | Apr 2014 | B2 |
8702726 | Gartstein et al. | Apr 2014 | B2 |
8734697 | Chen et al. | May 2014 | B2 |
8747362 | Terahara | Jun 2014 | B2 |
8771781 | Tokumoto et al. | Jul 2014 | B2 |
8821446 | Trautman et al. | Sep 2014 | B2 |
8834423 | Falo, Jr. et al. | Sep 2014 | B2 |
8900180 | Wolter et al. | Dec 2014 | B2 |
8911749 | Gharty-Tagoe et al. | Dec 2014 | B2 |
9114238 | Singh et al. | Aug 2015 | B2 |
9220678 | Kendall et al. | Dec 2015 | B2 |
9452280 | Singh et al. | Sep 2016 | B2 |
9498524 | Ghartey-Tagoe et al. | Nov 2016 | B2 |
9549746 | Woolfson | Jan 2017 | B2 |
9687640 | Trautman et al. | Jun 2017 | B2 |
9687641 | Singh et al. | Jun 2017 | B2 |
20010023324 | Pronovost et al. | Sep 2001 | A1 |
20010023351 | Eilers et al. | Sep 2001 | A1 |
20020006355 | Whitson | Jan 2002 | A1 |
20020016562 | Cormier et al. | Feb 2002 | A1 |
20020020688 | Sherman et al. | Feb 2002 | A1 |
20020032415 | Trautman et al. | Mar 2002 | A1 |
20020042589 | Marsoner | Apr 2002 | A1 |
20020045859 | Gartstein et al. | Apr 2002 | A1 |
20020045907 | Sherman et al. | Apr 2002 | A1 |
20020082543 | Park et al. | Jun 2002 | A1 |
20020087182 | Trautman et al. | Jul 2002 | A1 |
20020091357 | Trautman et al. | Jul 2002 | A1 |
20020096488 | Gulvin et al. | Jul 2002 | A1 |
20020123675 | Trautman et al. | Sep 2002 | A1 |
20020128599 | Cormier et al. | Sep 2002 | A1 |
20020133129 | Arias et al. | Sep 2002 | A1 |
20020133137 | Hofmann | Sep 2002 | A1 |
20020138049 | Allen et al. | Sep 2002 | A1 |
20020169411 | Sherman et al. | Nov 2002 | A1 |
20020177839 | Cormier et al. | Nov 2002 | A1 |
20020177858 | Sherman et al. | Nov 2002 | A1 |
20020188245 | Martin et al. | Dec 2002 | A1 |
20020188310 | Seward et al. | Dec 2002 | A1 |
20020193729 | Cormier et al. | Dec 2002 | A1 |
20020193819 | Porter et al. | Dec 2002 | A1 |
20030083645 | Angel et al. | May 2003 | A1 |
20030093028 | Spiegel | May 2003 | A1 |
20030093089 | Greenberg | May 2003 | A1 |
20030135167 | Gonnelli | Jul 2003 | A1 |
20030166624 | Gale et al. | Sep 2003 | A1 |
20030187394 | Wilkinson et al. | Oct 2003 | A1 |
20030195474 | Down et al. | Oct 2003 | A1 |
20030199810 | Trautman et al. | Oct 2003 | A1 |
20030199812 | Rosenberg | Oct 2003 | A1 |
20030208138 | Olson | Nov 2003 | A1 |
20030208167 | Prausnitz et al. | Nov 2003 | A1 |
20030212397 | Avrahami et al. | Nov 2003 | A1 |
20030220610 | Lastovich et al. | Nov 2003 | A1 |
20030220656 | Gartstein et al. | Nov 2003 | A1 |
20040049150 | Dalton et al. | Mar 2004 | A1 |
20040053894 | Mazess et al. | Mar 2004 | A1 |
20040062813 | Cormier et al. | Apr 2004 | A1 |
20040087893 | Kwon | May 2004 | A1 |
20040087992 | Gartstein et al. | May 2004 | A1 |
20040096455 | Maa et al. | May 2004 | A1 |
20040106904 | Gonnelli et al. | Jun 2004 | A1 |
20040143211 | Haider et al. | Jul 2004 | A1 |
20040146611 | Arias et al. | Jul 2004 | A1 |
20040164454 | Gartstein et al. | Aug 2004 | A1 |
20040181203 | Cormier et al. | Sep 2004 | A1 |
20040186419 | Cho | Sep 2004 | A1 |
20040204669 | Hofmann | Oct 2004 | A1 |
20040220535 | Canham | Nov 2004 | A1 |
20040236271 | Theeuwes et al. | Nov 2004 | A1 |
20040265365 | Daddona et al. | Dec 2004 | A1 |
20050049549 | Wong et al. | Mar 2005 | A1 |
20050065463 | Tobinga et al. | Mar 2005 | A1 |
20050089554 | Cormier et al. | Apr 2005 | A1 |
20050090803 | Sherman et al. | Apr 2005 | A1 |
20050096586 | Trautman et al. | May 2005 | A1 |
20050163827 | Zech et al. | Jul 2005 | A1 |
20050178760 | Chang et al. | Aug 2005 | A1 |
20050197308 | Dalton | Sep 2005 | A1 |
20050209565 | Yuzhakov et al. | Sep 2005 | A1 |
20050228340 | Cleary et al. | Oct 2005 | A1 |
20050256045 | Ameri et al. | Nov 2005 | A1 |
20050261631 | Clarke et al. | Nov 2005 | A1 |
20050271684 | Trautman et al. | Dec 2005 | A1 |
20060024358 | Santini et al. | Feb 2006 | A1 |
20060067943 | Maa et al. | Mar 2006 | A1 |
20060076718 | Sherman et al. | Apr 2006 | A1 |
20060095061 | Trautman et al. | May 2006 | A1 |
20060108914 | Young | May 2006 | A1 |
20060129174 | Gartstein et al. | Jun 2006 | A1 |
20060134188 | Podhaisky et al. | Jun 2006 | A1 |
20060149297 | Sherman et al. | Jul 2006 | A1 |
20060253079 | McDonough et al. | Nov 2006 | A1 |
20070027427 | Trautman et al. | Feb 2007 | A1 |
20070191761 | Boone et al. | Aug 2007 | A1 |
20070255251 | Panchula et al. | Nov 2007 | A1 |
20080009811 | Cantor | Jan 2008 | A1 |
20080009825 | Ringsred et al. | Jan 2008 | A1 |
20080039805 | Frederickson et al. | Feb 2008 | A1 |
20080114298 | Cantor et al. | May 2008 | A1 |
20080125743 | Yuzhakov | May 2008 | A1 |
20080183144 | Trautman et al. | Jul 2008 | A1 |
20080188771 | Boecker et al. | Aug 2008 | A1 |
20080195035 | Frederickson et al. | Aug 2008 | A1 |
20080203146 | Brandwein et al. | Aug 2008 | A1 |
20080208134 | Tomono | Aug 2008 | A1 |
20080214987 | Xu | Sep 2008 | A1 |
20080221532 | Ogawa | Sep 2008 | A1 |
20080269685 | Singh | Oct 2008 | A1 |
20090017210 | Andrianov et al. | Jan 2009 | A1 |
20090035446 | Kwon | Feb 2009 | A1 |
20090041810 | Andrianov et al. | Feb 2009 | A1 |
20090043279 | Kaspar et al. | Feb 2009 | A1 |
20090155330 | Ghartey-Tagoe et al. | Jun 2009 | A1 |
20090182306 | Lee | Jul 2009 | A1 |
20090216215 | Thalmann et al. | Aug 2009 | A1 |
20100028390 | Cleary et al. | Feb 2010 | A1 |
20100200494 | Storer | Aug 2010 | A1 |
20100228203 | Quan et al. | Sep 2010 | A1 |
20100247698 | Zhang et al. | Sep 2010 | A1 |
20110006458 | Sagi et al. | Jan 2011 | A1 |
20110028905 | Takada | Feb 2011 | A1 |
20110046638 | Gartstein et al. | Feb 2011 | A1 |
20110059150 | Kendall et al. | Mar 2011 | A1 |
20110098651 | Falo et al. | Apr 2011 | A1 |
20110121486 | Oh et al. | May 2011 | A1 |
20110160069 | Corrie et al. | Jun 2011 | A1 |
20110165236 | Chow et al. | Jul 2011 | A1 |
20110177139 | Hyungil et al. | Jul 2011 | A1 |
20110276027 | Trautman et al. | Nov 2011 | A1 |
20110276028 | Singh et al. | Nov 2011 | A1 |
20110280800 | Wu | Nov 2011 | A1 |
20110288484 | Kendall et al. | Nov 2011 | A1 |
20110288485 | Tokumoto et al. | Nov 2011 | A1 |
20110295205 | Kaufmann et al. | Dec 2011 | A1 |
20110306853 | Black et al. | Dec 2011 | A1 |
20120052120 | Castor | Mar 2012 | A1 |
20120123297 | Brancazio | May 2012 | A1 |
20120123387 | Gonzalez et al. | May 2012 | A1 |
20120130306 | Terahara et al. | May 2012 | A1 |
20120150023 | Kaspar et al. | Jun 2012 | A1 |
20120184906 | McAllister | Jul 2012 | A1 |
20120330250 | Kuwahara et al. | Dec 2012 | A1 |
20130131598 | Trautman et al. | May 2013 | A1 |
20130150822 | Ross | Jun 2013 | A1 |
20130287832 | O'Hagan et al. | Oct 2013 | A1 |
20130292868 | Singh et al. | Nov 2013 | A1 |
20130292886 | Sagi et al. | Nov 2013 | A1 |
20130303502 | Cavanagh et al. | Nov 2013 | A1 |
20140148846 | Pereira et al. | May 2014 | A1 |
20140180201 | Ding et al. | Jun 2014 | A1 |
20140248312 | Rappuoli et al. | Sep 2014 | A1 |
20140257188 | Kendall et al. | Sep 2014 | A1 |
20140272101 | Chen et al. | Sep 2014 | A1 |
20140276366 | Bourne et al. | Sep 2014 | A1 |
20140276378 | Chen et al. | Sep 2014 | A1 |
20140276474 | Ding et al. | Sep 2014 | A1 |
20140276580 | Le et al. | Sep 2014 | A1 |
20140276589 | Bayramov et al. | Sep 2014 | A1 |
20140330198 | Zhang et al. | Nov 2014 | A1 |
20150079133 | Ghartey-Tagoe et al. | Mar 2015 | A1 |
20150238413 | Mochizuki et al. | Aug 2015 | A1 |
20150297878 | Singh et al. | Oct 2015 | A1 |
20160058992 | Chen et al. | Mar 2016 | A1 |
20160067176 | Ding et al. | Mar 2016 | A1 |
20160135895 | Faasse et al. | May 2016 | A1 |
20160175572 | Crowley et al. | Jun 2016 | A1 |
20160374939 | Shastry et al. | Dec 2016 | A1 |
20170050010 | Mcallister et al. | Feb 2017 | A1 |
20170281535 | Singh et al. | Oct 2017 | A1 |
20170361079 | Trautman et al. | Dec 2017 | A1 |
Number | Date | Country |
---|---|---|
2205444 | Jun 1996 | CA |
2376285 | Dec 2000 | CA |
2316534 | Mar 2001 | CA |
2422907 | Apr 2002 | CA |
2889500 | May 2014 | CA |
102000020 | Jun 2011 | CN |
102580232 | Jul 2012 | CN |
02319591 | Nov 1974 | DE |
19518974 | Nov 1995 | DE |
19624578 | Jan 1998 | DE |
0156471 | Oct 1985 | EP |
0240593 | Oct 1987 | EP |
0301599 | Feb 1989 | EP |
0305123 | Mar 1989 | EP |
0312662 | Apr 1989 | EP |
0400249 | Dec 1990 | EP |
0407063 | Jan 1991 | EP |
0796128 | Sep 1997 | EP |
1086718 | Mar 2001 | EP |
1086719 | Mar 2001 | EP |
1174078 | Jan 2002 | EP |
2283809 | Feb 2011 | EP |
2399624 | Dec 2011 | EP |
2535602 | May 1984 | FR |
0783479 | Sep 1957 | GB |
2221394 | Feb 1990 | GB |
2277202 | Oct 1994 | GB |
46-037758 | Dec 1971 | JP |
60-242042 | Dec 1985 | JP |
62-213763 | Sep 1987 | JP |
01-264839 | Oct 1989 | JP |
02-009755 | Mar 1990 | JP |
03-151951 | Jun 1991 | JP |
05-123326 | May 1993 | JP |
05-162076 | Jun 1993 | JP |
06-238644 | Aug 1994 | JP |
07-132119 | May 1995 | JP |
08-502215 | Mar 1996 | JP |
09-051878 | Feb 1997 | JP |
54-028369 | Mar 1997 | JP |
09-140687 | Jun 1997 | JP |
09-211022 | Aug 1997 | JP |
10-328168 | Dec 1998 | JP |
11-230707 | Aug 1999 | JP |
11-509123 | Aug 1999 | JP |
2000-146777 | May 2000 | JP |
2000-147229 | May 2000 | JP |
2000-164890 | Jun 2000 | JP |
2000-194142 | Jul 2000 | JP |
2000-232095 | Aug 2000 | JP |
2000-232971 | Aug 2000 | JP |
2000-322780 | Nov 2000 | JP |
2000-323461 | Nov 2000 | JP |
2001-004442 | Jan 2001 | JP |
2001-138300 | May 2001 | JP |
2001-149485 | Jun 2001 | JP |
2001-157715 | Jun 2001 | JP |
2001-341314 | Dec 2001 | JP |
2002-000728 | Jan 2002 | JP |
2002-079499 | Mar 2002 | JP |
2002-151395 | May 2002 | JP |
2002-239014 | Aug 2002 | JP |
2002-301698 | Oct 2002 | JP |
2003-039399 | Feb 2003 | JP |
2003-048160 | Feb 2003 | JP |
2003-534881 | Nov 2003 | JP |
2004-065775 | Mar 2004 | JP |
2007-190112 | Jan 2006 | JP |
2006271781 | Oct 2006 | JP |
2006-341089 | Dec 2006 | JP |
2007-130030 | May 2007 | JP |
2007-536988 | Dec 2007 | JP |
2008-006178 | Jan 2008 | JP |
2008-074763 | Apr 2008 | JP |
2008-194288 | Aug 2008 | JP |
2009-082206 | Apr 2009 | JP |
2009-082207 | Apr 2009 | JP |
2009-201956 | Sep 2009 | JP |
2010-233673 | Oct 2010 | JP |
2010-233674 | Oct 2010 | JP |
20100064669 | Jun 2010 | KR |
2414255 | Mar 2011 | RU |
1641346 | Apr 1991 | SU |
1667864 | Aug 1991 | SU |
WO 1993015701 | Aug 1993 | WO |
WO 1993017754 | Sep 1993 | WO |
WO 1994023777 | Oct 1994 | WO |
WO 1995022612 | Aug 1995 | WO |
WO 1995033612 | Dec 1995 | WO |
WO 1996000109 | Jan 1996 | WO |
WO 1996017648 | Jun 1996 | WO |
WO 1996037155 | Nov 1996 | WO |
WO 1996037256 | Nov 1996 | WO |
WO 1997003629 | Feb 1997 | WO |
WO 1997003718 | Feb 1997 | WO |
WO 1997013544 | Apr 1997 | WO |
WO 1997048440 | Dec 1997 | WO |
WO 1997048441 | Dec 1997 | WO |
WO 1997048442 | Dec 1997 | WO |
WO 1998000193 | Jan 1998 | WO |
WO 1998028307 | Jul 1998 | WO |
WO 1999000155 | Jan 1999 | WO |
WO 1999029298 | Jun 1999 | WO |
WO 1999029364 | Jun 1999 | WO |
WO 1999-029365 | Jun 1999 | WO |
WO 1999049874 | Oct 1999 | WO |
WO 1999061888 | Dec 1999 | WO |
WO 1999064580 | Dec 1999 | WO |
WO 2000005166 | Feb 2000 | WO |
WO 2003026733 | Apr 2000 | WO |
WO 2000035530 | Jun 2000 | WO |
WO 2000070406 | Nov 2000 | WO |
WO 2000074763 | Dec 2000 | WO |
WO 2000074764 | Dec 2000 | WO |
WO 2000074765 | Dec 2000 | WO |
WO 2000074766 | Dec 2000 | WO |
WO 2000077571 | Dec 2000 | WO |
WO 2001008242 | Feb 2001 | WO |
WO 2001036037 | May 2001 | WO |
WO 2001036321 | May 2001 | WO |
WO 2001049362 | Jul 2001 | WO |
WO 2002002180 | Jan 2002 | WO |
WO 2002007543 | Jan 2002 | WO |
WO 2002007813 | Jan 2002 | WO |
WO 2002017985 | Mar 2002 | WO |
WO 2002030301 | Apr 2002 | WO |
WO 2002032331 | Apr 2002 | WO |
WO 2002032480 | Apr 2002 | WO |
WO 2002062202 | Aug 2002 | WO |
WO 2002064193 | Aug 2002 | WO |
WO 2002072189 | Sep 2002 | WO |
WO 2002085446 | Oct 2002 | WO |
WO 2002091922 | Nov 2002 | WO |
WO 2002100474 | Dec 2002 | WO |
WO 2003024290 | Mar 2003 | WO |
WO 2003024518 | Mar 2003 | WO |
WO 2004000389 | Dec 2003 | WO |
WO 2004009172 | Jan 2004 | WO |
WO 2004024224 | Mar 2004 | WO |
WO 2004030649 | Apr 2004 | WO |
WO 2004076339 | Sep 2004 | WO |
WO 2004105729 | Dec 2004 | WO |
WO 2004110717 | Dec 2004 | WO |
WO 2005002453 | Jan 2005 | WO |
WO 2005046769 | May 2005 | WO |
WO 2005065765 | Jul 2005 | WO |
WO 2005082596 | Sep 2005 | WO |
WO 2005089857 | Sep 2005 | WO |
WO 2005094526 | Oct 2005 | WO |
WO 2005099751 | Oct 2005 | WO |
WO 2005112984 | Dec 2005 | WO |
WO 2006020842 | Feb 2006 | WO |
WO 2006056795 | May 2006 | WO |
WO 2006062848 | Jun 2006 | WO |
WO 2006086742 | Aug 2006 | WO |
WO 2006101459 | Sep 2006 | WO |
WO 2007002521 | Jan 2007 | WO |
WO 2007002522 | Jan 2007 | WO |
WO 2007002523 | Jan 2007 | WO |
WO 2007012114 | Feb 2007 | WO |
WO 2007030477 | Mar 2007 | WO |
WO 2007061964 | May 2007 | WO |
WO 2007061972 | May 2007 | WO |
WO 2007075806 | Jul 2007 | WO |
WO 2007081430 | Jul 2007 | WO |
WO 2007124411 | Nov 2007 | WO |
WO 2008011625 | Jan 2008 | WO |
WO 2008015236 | Feb 2008 | WO |
WO 2008024141 | Feb 2008 | WO |
WO 2008091602 | Jul 2008 | WO |
WO 2008130587 | Oct 2008 | WO |
WO 2008139648 | Nov 2008 | WO |
WO 2009039013 | Mar 2009 | WO |
WO 2009048607 | Apr 2009 | WO |
WO 2009054988 | Apr 2009 | WO |
WO 2009142741 | Nov 2009 | WO |
WO 2010040271 | Apr 2010 | WO |
WO 2010124255 | Oct 2010 | WO |
WO 2011121023 | Oct 2011 | WO |
WO 2011140240 | Oct 2011 | WO |
WO 2011140274 | Oct 2011 | WO |
WO 2012153266 | Jan 2012 | WO |
WO 2012054582 | Apr 2012 | WO |
WO 2012122163 | Sep 2012 | WO |
WO 2012127249 | Sep 2012 | WO |
WO 2013172999 | Nov 2013 | WO |
WO 2014004301 | Jan 2014 | WO |
WO 2014077244 | May 2014 | WO |
WO 2014100750 | Jun 2014 | WO |
WO 2014144973 | Sep 2014 | WO |
WO 2014150069 | Sep 2014 | WO |
WO 2014150285 | Sep 2014 | WO |
WO 2014151654 | Sep 2014 | WO |
WO 2014164314 | Oct 2014 | WO |
WO 2016033540 | Mar 2016 | WO |
WO 2016036866 | Mar 2016 | WO |
WO 2016073908 | May 2016 | WO |
WO 2017004067 | Jan 2017 | WO |
Entry |
---|
Lutrol® F 68 NF, as accessed from the Internet on Sep. 5, 2016, available from http://www2.basf.us/Pharma/pdf/Lutrol_F_68.pdf. |
“Eudragit EPO Readymix—Taste masking and moisture protection have never been easier” Evonik Industries, Evonik Industries AG, Pharma Polymers & Services, Nov. 2014. |
International Search Report from International Patent Application No. PCT/US2014/022836 dated May 9, 2015. |
Avcin et al., “Subcutaneous nodule after vaccination with an aluminum-containing vaccina”, Acta Dermatoven, APA, vol. 17, No. 4, pp. 182-184 (2008). |
Corbett et al., “Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model”, PLOS one,vol. 5, No. 10, pp. 1-9 (2010). |
Database WPI / Thomson, Accession No. 2014-V89218, Gao et al., “Soluble microneedle patch useful for transdermal administration of vaccine, comprises water-soluble polymer material as matrix material and soluble microneedle main portion”, Application No. CN104027324A, Tech Inst Phys. & Chem. Chinese Acad., 3 pages (2014). |
Ghosh et al., “Influence of critical parameters of nanosuspension formulation on permeability of a poorly soluble drug through the skin-A case study”, vol. 14, No. 3, pp, 1108-1117 (2013). |
Guo et al., “Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant”, Int. J. Pharm., vol. 447, No. 1-2, pp. 22-30 (2013). |
Gupta, “Aluminum compounds as vaccine adjuvants”, Adv. Drug Deliv. Rev., vol. 32, No. 3, pp. 155-172 (1998) Abstract Only. |
Gupta and Rost, “Aluminum compounds as vaccine adjuvants”, Vaccine adjuvants: Preparation Methods and Research Protocols, O'Hagan, ed., Humana Press, Inc., Totowa, New Jersey, Meth. Mol. Med., vol. 42, No. 4, No. 4, pp. 65-89 (2000). |
International Search Report from International Patent Application No. PCT/US2015/047563 dated Nov. 20, 2015. |
International Search Report from International Patent Application No. PCT/US2015/048161 dated Nov. 26, 2015. |
Kuroda et al., “Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects”, Int. Rev. Immunol., vol. 32, No. 2, pp. 209-220 (2013). |
Munks et al., “Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo”, Blood, vol. 116, No. 24, pp. 5191-5199 (2010). |
Petrovsky and Aguilar, “Vaccine adjuvants: current state and future trends”, Immunol. Cell Biol., vol. 82, No. 5, pp. 488-496 (2004). |
Pittman, “Aluminum-containing vaccine associated adverse events: role of route of administration and gender”, Vaccine, vol. 20, pp. s48-s50 (2002). |
Prausnitz, “Microneedie-based vaccines”, Curr. Top. Microbiol. Immunol., vol. 333, pp. 369-393 (2009). |
Sayers et al., “Vaxjo: A Web-Based Vaccine Adjuvant Database and Its Application for Analysis of Vaccine Adjuvants and Their Uses in Vaccine Development”, J. Biomed. Biotechnol., vol. 2012, Article ID: 831486, 13 pages, doi:10.1155/2012/831486 (2011). |
White et al., “Studies on antibody production. III. The alum granuloma”, J. Exp. Med., vol. 102, No. 1, pp. 73-82 (1955). |
International Search Report from International Patent Application No. PCT/US2015/059559 dated Jan. 21, 2016. |
Keitel et al., “A randomized clinical trail of acellular pertussis vaccines in healthy adults: Dose-response comparisons of 5 vaccines and implications for booster immunization”, J. Infect. Dis., vol. 180, pp. 397-403 (1999). |
Vitiello et al., “Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection”, J. Clin. Invest., vol. 95, pp. 341-349 (1995). |
International Search Report from International Patent Application No. PCT/US2014/021841 dated Aug. 11, 2014. |
International Search Report from International Patent Application No. PCT/US2014/026179 dated Jul. 18, 2014. |
International Search Report from International Patent Application No. PCT/US2014/029601 dated Jul. 1, 2014. |
Chun, et al., “An array of hollow microcapiliaries for the controlled injection of genetic materials into animal/plant cells.” IEEE Workshop on Micro Electro Mechanical Systems, pp. 406-411, (1999). |
“Extend”, Merriam-Webster Online Dictionary, 6 pages, Downloaded on Sep. 7, 2010 from <http://www.merriam-webster.com/dictionary/extend>. |
“Extend”, Macmillan Online Dictionary, 5 pages, Downloaded on Sep. 7, 2010 from <http://www.macmillandictionary.com/dictionary/american/extend>. |
Henry, et al., “Micromachined microneedles for transdermal delivery of drugs”, IEEE Workshop on Micro Electro Mechanical Systems, New York, NY, pp. 494-498, (1998). |
Henry, et al., “Microfabricated microneedles: A novel approach to transdermal drug delivery”, J. Pharmaceutical Science, vol. 87, No. 8, pp. 922-925, (1998). |
“Heparin Pregnancy and Breast Feeding Warnings”, Drugs.com, Accessed Oct. 8, 2009, <http://www.drugs.com/pregnancy/heparin.html>. |
International Search Report from International Patent Application No. PCT/US2000/015612 dated Sep. 7, 2000. |
International Search Report from International Patent Application No. PCT/US2000/015613 dated Sep. 6, 2000. |
International Search Report from International Patent Application No. PCT/US2000/015614 dated Sep. 6, 2000. |
International Search Report from International Patent Application No. PCT/US2001/031977 dated Apr. 29, 2002. |
International Search Report from International Patent Application No. PCT/US2001/031978 dated Apr. 29, 2002. |
International Search Report from International Patent Application No. PCT/US2002/014624 dated Sep. 3, 2002. |
International Search Report from International Patent Application No. PCT/US2002/029228 dated Apr. 23, 2003. |
International Search Report from International Patent Application No. PCT/US2002/029245 dated Dec. 27, 2002. |
International Search Report from International Patent Application No. PCT/US2004/005382 dated Nov. 25, 2004. |
International Search Report from International Patent Application No. PCT/US2004/017255 dated May 24, 2005. |
International Search Report from International Patent Application No. PCT/US2005/009854 dated Jul. 3, 2008. |
International Search Report from International Patent Application No. PCT/US2008/000824 dated Jul. 18, 2008. |
International Search Report from International Patent Application No. PCT/US2008/004943 dated Jun. 9, 2009, application now published as International Publication No. WO2008/130587 dated Oct. 30, 2008. |
International Search Report from International Patent Application No. PCT/US2008/011635 dated Dec. 19, 2008, application now published as International Publication No. WO2009/048607 dated Apr. 16, 2009. |
International Search Report from International Patent Application No. PCT/US2010/032299 dated Dec. 10, 2010, application now published as International Publication No. WO2010/124255 dated Oct. 28, 2010. |
International Search Report from International Patent Application No. PCT/US2013/077281 dated Mar. 4, 2013. |
International Search Report from International Patent Application No. PCT/US2014/022087 dated May 23, 2014. |
International Search Report from International Patent Application No. PCT/US2014/022859 dated May 26, 2014. |
Matriano, et al., “Macroflux(R) microprojection array patch technology: A new and efficient approach for intracutaneous immunization”, Pharm. Res., vol. 19, No. 1, pp. 63-70, (2002). |
McAllister, et al., “Micromachined microneedles for transdermal drug delivery”, Am. Inst. Chem. Eng., 1998 Annual Meeting, Miami Beach, FL, Nov. 15-20, Drug Delivery II, pp. 1-4. |
Mikszta, et al., “Improvred genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery”, Nat. Med., vol. 8, No. 4, pp. 415-419, (2002). |
Mikszta, et al., “Protective immunization against inhalation anthrax: A comparison of minimally invasive delivery platforms”, J. Inf. Dis., vol. 191, No. 2, pp. 278-288, (2005). |
Papautsky, et al., “Micromachined Pipette Arrays,” MPA Proceedings—19th international Conference—IEEE/EMBS, Chicago, IL, USA, pp. 2281-2284 (1997). |
Park et al., “Biodegradable polymer microneedles: Fabrication, mechanics, and transdermal drug delivery”, J. Contr. Rel., vol. 104, pp. 51-66 (2005). |
Park, et al., “Polymer Microneedles for Controlled-Release Drug Delivery,” Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NE, vol. 23, No. 5, pp. 1008-1019 (2006). |
Prausnitz, et al., “Transdermal transport efficiency during skin electroporation and iontophoresis”, J. Contr. Release, vol. 38, pp. 205-217, (1996). |
Prausnitz, “Transdermal delivery of macromolecules: Recent advances by modification of skin's barrier properties”, ACS Symposium Series No. 675, Therapeutic Protein And Peptide Formulation And Delivery, American Chemical Society, Washington DC, Chapter 8, pp. 124-153, (1997). |
Rydberg, et al., “Low-molecular-weight heparin preventing and treating DVT”, Am. Fam. Physician, vol. 59, No. 6, pp. 1607-1612, (1999). |
Sivamani, et al., “Microneedles and transdermal applications”, Exp. Opin. Drug Del., vol. 4, No. 1, pp. 19-25, (2007). |
Wouters, et al., “Microelectrochemical systems for drug delivery”, Electrochimica Acta., vol. 42, pp. 3385-3390, (1997). |
Xia, et al., “Soft Lithography”, Agnew. Chem. Int. Ed., vol. 37, pp. 551-575, (1998). |
Xia, et al., “Soft Lithography”, Annu. Rev. Mater. Sci., vol. 28, pp. 153-184 (1998). |
International Search Report from International Patent Application No. PCT/US2011/035221 dated Jan. 10, 2012, application now published as International Publication No. WO2011/140240 dated Nov. 10, 2011. |
International Search Report from International Patent Application No. PCT/US2016/039864 dated Sep. 23, 2016. |
Makaida et al., “Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier”, Polymers (Basel), vol. 3 No. 3, pp. 1377-1397 (2011). |
Julinova et al., “Initiating biodegradation of polyvinylpyrrolidone in aqueous aerobic environment”, Proceedings of ECOpole, vol. 6, No. 1, pp. 121-127 (2012). |
Kunduru et al., “Biodegradable polymers: Medical Applications”, Encyclopedia of Polymer Science and Technology, pp. 1-22 (2016) DOI: 10.1002/0471440264.pst027.pub2. |
Polysorbate 80, Material Safety Data Sheet, CAS#: 9005-65-6, Science Lab.com, Inc., 14025 Smith Rd., Houston, Texas 77396, 5 pages, Last updated May 21, 2013. |
Number | Date | Country | |
---|---|---|---|
20140276474 A1 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
61792715 | Mar 2013 | US |